期刊文献+

奥扎格雷和血塞通注射液联用治疗不稳定性心绞痛的疗效观察

Austria to grip the grey and the thrombosis passes the inoculation fluid association with the treatment unstable angina pectoris curative effect observation
原文传递
导出
摘要 目的:观察奥扎格雷和血塞通注射液治疗不稳定性心绞痛的疗效.方法:将56例冠心病心绞痛患者随机分为两组,对照组组给予阿司匹林、硝酸酯类、β-受体阻滞剂等治疗;治疗组在此基础上加奥扎格雷80mg,静脉滴注,1次/d,血塞通注射液400mg,静脉滴注,1次/d,连用2周.结果:总有效率治疗组为89.47%,对照组为61.11%,总有效率比较有显著差异(P〈0.05).结论:奥扎格雷与血塞通注射液联合应用治疗不稳定性心绞痛,能明显提高疗效. Objective Observes Austria to grip the grey and the thrombosis passes the inoculation fluid treatment unstable angina pectoris the curative effect. Methods: Divides into two groups stochastically 56 example coronary disease angina pectoris patient, the control group group gives the aspirin, the nitric acid ester,beta -- treatments and so on acceptor retarder;The treatment group adds Austria in this foundation to grip grey 80 nag,the vein drop note,1/d,the thrombosis passes inoculation fluid 400mg,the vein drop note, 1 /d,is used together 2 weeks. Results.. The total effectiveness treatment group is 89.47 %, the control group is 61.11%, the total effectiveness comparison has the remarkable difference (P〈0.05). Conclusion: Austria grips the grey and the thrombosis pas- ses the inoculation fluid union application treatment unstable angina pectoris,can enhance the curative effect obviously.
作者 劳若平
出处 《按摩与康复医学》 2011年第5期100-101,共2页 Chinese Manipulation and Rehabilitation Medicine
关键词 奥扎格雷 血塞通注射液 不稳定性心绞痛 疗效观察 Austria grips the grey Thrombosis to pass the inoculation fluid Unstable angina pectoris Curative effect observation
  • 相关文献

参考文献3

二级参考文献20

  • 1屈晓冰,孙振球,陈美娟,陈珑珑.冠心病患者P-选择素水平及其与冠状动脉病变程度间的关系[J].中华流行病学杂志,2005,26(8):617-621. 被引量:33
  • 2Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies : Part I. Circulation, 2003,108 : 1664-1672.
  • 3Shebuski R J, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther, 2002,300 : 729-735.
  • 4Carter AM, Anagnostopoulou K, Mansfield MW, et al. Soluble P-selectin levels, P-selectin polyrnorphisms and cardiovascular disease. J Thromb Haemost,2003,1 : 1718-1723.
  • 5Braunwald E, Antman EM, Beasley JW, et ah ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2000, 36:970-1062.
  • 6Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol, 1983,51 : 606.
  • 7Smith SC, Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines ( committee to revise the 1993 guidelines for percutaneous translurninal coronary angioplasty ). J Am Coll Cardiol,2001,37 : 2215-2239.
  • 8Johnson RC, Chapman SM, Dong ZM, et al. Absence of P-selectin delays fatty streak formation in mice. J Clin Invest, 1997, 99 :1037-1040.
  • 9Dong ZM, Brown AA, Wagner DD. Prominent role of P-selectin in the development of advance atherosclerosis in apoE-deficient mice.Circulation, 2000,101:2290-2295.
  • 10Phillips JW, Barringhaus KG, Sanders JM, et al. Single injection of P-selectin or P-selectin glycoprotein ligand 1 monoclonal antibody blocks neointima formation after arterial injury in apolipoprotein E-deficient Mice. Circulation,2003,107 : 2244-2249.

共引文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部